The Systemic Immune-Inflammation Index is an Independent Predictor of Survival in Breast Cancer Patients

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (vol 68, pg 394, 2018). CA Cancer J Clin. 2020;70(4):313.
   Web of Science ®Google Scholar
• Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res. 2017;29(1):1–10. doi:10.21147/j.issn.1000-9604.2017.01.01
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology. 2017;49(2):166–171. doi:10.1016/j.pathol.2016.11.006
   PubMed Web of Science ®Google Scholar
• Yip C-H, Rhodes A. Estrogen and progesterone receptors in breast cancer. Fut Oncol. 2014;10(14):2293–2301. doi:10.2217/fon.14.110
   PubMed Web of Science ®Google Scholar
• Krishnamurti U, Silverman JF. HER2 in Breast Cancer: a Review and Update. Adv Anat Pathol. 2014;21(2):100–107. doi:10.1097/PAP.0000000000000015
   PubMed Web of Science ®Google Scholar
• Bertucci F, Goncalves A. Immunotherapy in breast cancer: the emerging role of PD-1 and PD-L1. Curr Oncol Rep. 2017;19(10). doi:10.1007/s11912-017-0627-0
   PubMed Web of Science ®Google Scholar
• Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121–126. doi:10.4103/aam.aam_56_18
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025
   PubMed Web of Science ®Google Scholar
• Tobias DK, Akinkuolie AO, Chandler PD, et al. Markers of inflammation and incident breast cancer risk in the women’s health study. Am J Epidemiol. 2018;187(4):705–716. doi:10.1093/aje/kwx250
   PubMed Web of Science ®Google Scholar
• Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol. 2014;382(1):673–682. doi:10.1016/j.mce.2013.06.003
   PubMed Web of Science ®Google Scholar
• Corbeau I, Thezenas S, Maran-Gonzalez A, Colombo P-E, Jacot W, Guiu S. Inflammatory blood markers as prognostic and predictive factors in early breast cancer patients receiving neoadjuvant chemotherapy. Cancers. 2020;12(9):2666. doi:10.3390/cancers12092666
   PubMed Web of Science ®Google Scholar
• Graziano V, Grassadonia A, Iezzi L, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33–38. doi:10.1016/j.breast.2018.12.014
   PubMed Web of Science ®Google Scholar
• Xu J, Ni C, Ma C, et al. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy. Clin Transl Oncol. 2017;19(8):989–996. doi:10.1007/s12094-017-1630-5
   PubMed Web of Science ®Google Scholar
• Wang C, Jin S, Xu S, Cao S. High Systemic Immune-Inflammation Index (SII) represents an unfavorable prognostic factor for small cell lung cancer treated with etoposide and platinum-based chemotherapy. Lung. 2020;198(2):405–414. doi:10.1007/s00408-020-00333-6
   PubMed Web of Science ®Google Scholar
• Li S, Yang Z, Du H, Zhang W, Che G, Liu L. Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score-matching study. ANZ J Surg. 2019;89(11):E507–E13. doi:10.1111/ans.15480
   PubMed Web of Science ®Google Scholar
• Okadome K, Baba Y, Yagi T, et al. Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer. Ann Surg. 2020;271(4):693–700. doi:10.1097/SLA.0000000000002985
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:10.3322/caac.21388
   PubMed Web of Science ®Google Scholar
• Cserni G, Chmielik E, Cserni B, Tot T. The new TNM-based staging of breast cancer. Virchows Arch. 2018;472(5):697–703. doi:10.1007/s00428-018-2301-9
   PubMed Web of Science ®Google Scholar
• Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6(12):718–730. doi:10.1038/nrclinonc.2009.166
   PubMed Web of Science ®Google Scholar
• Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320–327. doi:10.1016/S0960-9776(03)00106-1
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–216. doi:10.1093/jnci/92.3.205
   PubMed Web of Science ®Google Scholar
• Amat S, Penault-Llorca F, Cure H, et al. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol. 2002;20(4):791–796.
   PubMed Web of Science ®Google Scholar
• Kaba H, Fukuda H, Yamamoto S, Ohashi Y. Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0. Gan to Kagaku Ryoho. 2004;31(8):1187–1192.
   PubMedGoogle Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):E493–E503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025
   PubMed Web of Science ®Google Scholar
• Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol. 2019;40(3):228–242. doi:10.1016/j.it.2019.01.006
   PubMed Web of Science ®Google Scholar
• Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 2018;33(6):965–983. doi:10.1016/j.ccell.2018.03.002
   PubMed Web of Science ®Google Scholar
• Yang J, Xu J, Ying E, Sun T. Predictive and prognostic value of circulating blood lymphocyte subsets in metastatic breast cancer. Cancer Med. 2019;8(2):492–500. doi:10.1002/cam4.1891
   PubMed Web of Science ®Google Scholar
• Powell DR, Huttenlocher A. Neutrophils in the Tumor Microenvironment. Trends Immunol. 2016;37(1):41–52. doi:10.1016/j.it.2015.11.008
   PubMed Web of Science ®Google Scholar
• Rakic A, Beaudry P, Mahoney DJ. The complex interplay between neutrophils and cancer. Cell Tissue Res. 2018;371(3):517–529. doi:10.1007/s00441-017-2777-7
   PubMed Web of Science ®Google Scholar
• Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134–147. doi:10.1038/nri.2017.105
   PubMed Web of Science ®Google Scholar
• Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1). doi:10.1186/s13045-018-0669-2
   PubMed Web of Science ®Google Scholar
• Gresele P, Malvestiti M, Momi S. Anti-platelet treatments in cancer: basic and clinical research. Thromb Res. 2018;164:S106–S11. doi:10.1016/j.thromres.2017.12.016
   PubMed Web of Science ®Google Scholar
• Dupre A, Malik HZ. Inflammation and cancer: what a surgical oncologist should know. Eur J Surg Oncol. 2018;44(5):566–570. doi:10.1016/j.ejso.2018.02.209
   PubMed Web of Science ®Google Scholar
• Hall M, Liu H, Malafa M, et al. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer. 2016;4(1). doi:10.1186/s40425-016-0164-7.
   PubMed Web of Science ®Google Scholar
• Zhou G, Sprengers D, Boor PPC, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology. 2017;153(4):110. doi:10.1053/j.gastro.2017.06.017
   Web of Science ®Google Scholar
• Zhang Y, Xiao G, Wang R. Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis. Cancer Manag Res. 2019;11:4185–4200. doi:10.2147/CMAR.S190006
   PubMed Web of Science ®Google Scholar
• Chen J-H, Zhai E-T, Yuan Y-J, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.6261
   PubMed Web of Science ®Google Scholar
• Dong M, Shi Y, Yang J, et al. Prognostic and clinicopathological significance of systemic immune-inflammation index in colorectal cancer: a meta-analysis. Ther Adv Med Oncol. 2020;12:175883592093742. doi:10.1177/1758835920937425
   Web of Science ®Google Scholar
• Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer. 2018;9(18):3295–3302. doi:10.7150/jca.25691
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang R, Ma W, et al. Systemic immune-inflammation index predicts prognosis of bladder cancer patients after radical cystectomy. Ann Transl Med. 2019;7(18):431.
   PubMed Web of Science ®Google Scholar
• Hu B, Yang X-R, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222. doi:10.1158/1078-0432.CCR-14-0442
   PubMed Web of Science ®Google Scholar
• Murthy P, Zenati MS, Al Abbas AI, et al. Prognostic value of the Systemic Immune-Inflammation Index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 2020;27(3):898–906. doi:10.1245/s10434-019-08094-0
   PubMed Web of Science ®Google Scholar
• Wang P, Yue W, Li W, et al. Systemic immune-inflammation index and ultrasonographic classification of breast imaging-reporting and data system predict outcomes of triple-negative breast cancer. Cancer Manag Res. 2019;11:813–819. doi:10.2147/CMAR.S185890
   PubMed Web of Science ®Google Scholar
• Liu J, Shi Z, Bai Y, Liu L, Cheng K. Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer. Cancer Manag Res. 2019;11:4471–4480. doi:10.2147/CMAR.S197623
   PubMed Web of Science ®Google Scholar
• Jiang L, Fang J, Ding J. High systemic immune-inflammation index predicts poor survival in patients with human epidermal growth factor receptor-2 positive breast cancer receiving adjuvant trastuzumab. Cancer Manag Res. 2020;12:475–484. doi:10.2147/CMAR.S231444
   PubMed Web of Science ®Google Scholar
• Chen L, Kong X, Wang Z, Wang X, Fang Y, Wang J. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy. J Cell Mol Med. 2020;24(5):2993–3021. doi:10.1111/jcmm.14934
   PubMed Web of Science ®Google Scholar
• Thompson N, Storr S, Zhang S, Martin S. Lymphovascular invasion: assessment and prognostic impact in melanoma and breast cancer. Histol Histopathol. 2015;30(9):1001–1009. doi:10.14670/HH-11-615
   PubMed Web of Science ®Google Scholar